{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/management/management/","result":{"pageContext":{"chapter":{"id":"e25197e7-f16f-5181-8e1c-dafe0b580500","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 9e8f85d2-8c11-4370-abae-7e7022f51c52 --><h2>Scenario: Management of vitamin D deficiency or insufficiency in adults</h2><!-- end field 9e8f85d2-8c11-4370-abae-7e7022f51c52 -->","summary":"Covers the management of adults with confirmed vitamin D deficiency or insufficiency.","htmlStringContent":"<!-- begin item 390ef5cb-b7bd-471d-868d-50ce7b443af8 --><!-- begin field ad80ae30-f97b-4e33-9508-acbc015c51cc --><p>From age 18 years onwards.</p><!-- end field ad80ae30-f97b-4e33-9508-acbc015c51cc --><!-- end item 390ef5cb-b7bd-471d-868d-50ce7b443af8 -->","topic":{"id":"3a69f47b-0066-5318-ba94-a0776d1f423d","topicId":"77754106-b68f-4177-9b0c-fcfcc0541b9a","topicName":"Vitamin D deficiency in adults - treatment and prevention","slug":"vitamin-d-deficiency-in-adults-treatment-prevention","lastRevised":"Last revised in December 2020","chapters":[{"id":"396b28e6-6484-5cca-9444-794f9df7f5ba","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"94588ae1-a24e-565d-9ada-cde0a2e0bb55","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2ca45f23-b265-5722-95e2-d6af017261b5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"e5e6b83a-db43-5cc7-9eb9-cd7edfd8b8bb","slug":"changes","fullItemName":"Changes"},{"id":"a048ffa1-ca03-5795-a6c7-8193bc080874","slug":"update","fullItemName":"Update"}]},{"id":"ea8bab75-416a-570c-906e-886a7bf19f25","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"35b5c184-9d67-5712-b377-e307f07bcb3b","slug":"goals","fullItemName":"Goals"},{"id":"3eba5c68-debd-5037-b81a-cb5e1013a594","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ea5df35b-0a9c-5d62-b0aa-9a555ce5f252","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"38f7be89-95a4-5482-9d9a-f44df577e6da","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"03ca12c7-b5b1-5bee-aa63-4e811d7a3a85","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - options for local implementation"},{"id":"67faf89f-36e5-5dfc-aff0-ccefe829b44e","slug":"nice-quality-standards","fullItemName":"NICE Quality Standards"}]},{"id":"d440bdfb-8a77-5d5a-8d51-42ade33261e5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"311eb939-36fd-5253-ac04-84819593f5d2","slug":"definition","fullItemName":"Definition"},{"id":"c4d9232d-8052-54ae-86f2-4125977b1aa8","slug":"causes","fullItemName":"Causes"},{"id":"837233ab-36b4-51df-9a88-326d3790e336","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"993c0290-b517-5988-be9a-f3ad93c5b0db","slug":"prevalence","fullItemName":"Prevalence"},{"id":"322a14cb-1bf8-5d57-ab4c-efb44f5d7e34","slug":"prognosis","fullItemName":"Prognosis"},{"id":"dac16ea5-b0b9-5165-9ed8-315132d29361","slug":"complications","fullItemName":"Complications"}]},{"id":"99484033-b20e-578b-b849-3a7452cf0ae9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b6fc715d-c19d-53d6-9397-c14378e40e3d","slug":"who-to-test","fullItemName":"Who to test"},{"id":"3a88b9b6-9837-5141-b74f-8167b79b602d","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"17ad9658-809e-5a65-943b-4c7f2a735afb","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"280d7a62-4835-58e6-b17c-7af17719f640","fullItemName":"Management","slug":"management","subChapters":[{"id":"e25197e7-f16f-5181-8e1c-dafe0b580500","slug":"management","fullItemName":"Scenario: Management"},{"id":"0d8d6905-0318-5b5c-88cc-13505f814efa","slug":"prevention","fullItemName":"Scenario: Prevention"}]},{"id":"8ab90bd1-85fe-5075-84fd-a634420ee1dc","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"13fe48bf-c971-5872-be15-68142508b80a","slug":"high-dose-vitamin-d","fullItemName":"High-dose vitamin D"},{"id":"5556b410-0169-5dfa-8b9e-265e042b7ad6","slug":"calcium-supplements","fullItemName":"Calcium supplements"},{"id":"df2f2e94-cfc6-5861-a569-ba2a7e170972","slug":"calcium-vitamin-d-combination-products","fullItemName":"Calcium and vitamin D combination products"}]},{"id":"bbde9f9a-1785-5bb8-accc-6522e50f3da3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a728b337-b5eb-54ce-aa84-fd41e9ab7bfe","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"328964a6-39f5-51ab-b702-b70e97622341","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f8757527-5aee-52e4-927c-3fc956a1a96f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c1c7faf8-f290-5977-8495-18863e441219","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"cfe620c3-2dcb-5d24-a733-8da8eb9076e4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"92307da5-fba2-5898-a234-2e16112ec3c6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"601d0c22-b19e-50fd-a325-c5d36e5adb83","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"280d7a62-4835-58e6-b17c-7af17719f640","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"c348608b-b561-5134-a97b-2cb9b0d10438","slug":"who-to-treat","fullItemName":"Who to treat","depth":3,"htmlHeader":"<!-- begin field cc9bce15-8d15-4c6f-bfdb-13cf420b31cd --><h3>Who should be treated for vitamin D deficiency or insufficiency?</h3><!-- end field cc9bce15-8d15-4c6f-bfdb-13cf420b31cd -->","summary":null,"htmlStringContent":"<!-- begin item f83b8d90-ac66-438e-b567-f0f7a63a92e9 --><!-- begin field 4aa9c751-36f9-4a4d-a1f4-ab2f1899a1ce --><ul><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/management/management/#how-to-treat\">Treat</a> for vitamin D deficiency if serum 25-hydroxyvitamin D (25[OH]D) levels are </strong>less than 25 nmol/L.</li><li><strong>If serum 25(OH)D levels are adequate (that is, above 25 nmol/L), </strong>advise on <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/management/prevention/\">measures to prevent vitamin D deficiency</a>.<ul><li>If the person has musculoskeletal symptoms (such as muscle pain or weakness) despite adequate serum 25(OH)D levels, consider an <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/diagnosis/differential-diagnosis/\">alternative diagnosis</a>.</li></ul></li><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/management/management/#how-to-treat\">Treat</a></strong><strong> for vitamin D insufficiency if serum 25(OH)D levels are </strong>in the range of 25–50 nmol/L and the person:<ul><li>Has a fragility fracture, documented osteoporosis, or high fracture risk.</li><li>Is being treated with an antiresorptive drug for bone disease.</li><li>Has raised parathyroid hormone levels.</li><li>Is taking an antiepileptic drug or an oral corticosteroid, or is on long-term treatment with other <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/background-information/causes/\">drugs</a> known to cause vitamin D deficiency, such as colestyramine.</li><li>Has a malabsorption disorder (for example Crohn's disease) or other <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/background-information/causes/\">condition</a> known to cause vitamin D deficiency, such as chronic kidney disease. </li></ul></li></ul><!-- end field 4aa9c751-36f9-4a4d-a1f4-ab2f1899a1ce --><!-- end item f83b8d90-ac66-438e-b567-f0f7a63a92e9 -->","subChapters":[{"id":"a2e640d3-53b7-5ddf-9d8c-3dbecd20976a","slug":"basis-for-recommendation-545","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field df1aca27-356f-4dad-a001-c8f5fef04005 --><h4>Basis for recommendation</h4><!-- end field df1aca27-356f-4dad-a001-c8f5fef04005 -->","summary":null,"htmlStringContent":"<!-- begin item 545df68f-0c1d-4814-9696-903d32c2a678 --><!-- begin field d64c81ba-34f1-4dfb-8636-aa1c56b9f083 --><p>This recommendation is largely based on the National Osteoporosis Society (NOS) guideline <em>Vitamin D and bone health: a practical clinical guideline for patient management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">National Osteoporosis Society, 2013</a>] and Scientific Advisory Committee on Nutrition (SACN) guideline <em>Vitamin D and Health</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">SACN, 2016</a>].</p><ul><li>CKS and NOS recommend treating people with serum 25-hydroxyvitamin D (25[OH]D) levels in the range of 25-50 nmol/L who are taking an antiepileptic drug or an oral corticosteroid. Based on good clinical practice, CKS recommends also treating people on long-term treatment with other drugs known to cause vitamin D deficiency.</li><li>CKS and NOS recommends treating people with 25(OH)D levels in the range of 25-50 nmol/L who have a malabsorption disorder. Based on good clinical practice, CKS recommends also treating people with other conditions known to cause vitamin D deficiency.</li><li>The recommendation to consider an alternative diagnosis if there are musculoskeletal symptoms at serum 25(OH)D above 50 nmol/L is extrapolated from expert opinion in the NOS vitamin D guideline for children and young people, which states that if a child or young person treated for vitamin D deficiency remains symptomatic despite satisfactory 25(OH)D concentrations, symptoms are unlikely to be related to vitamin D deficiency [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">National Osteoporosis Society, 2015</a>].</li></ul><!-- end field d64c81ba-34f1-4dfb-8636-aa1c56b9f083 --><!-- end item 545df68f-0c1d-4814-9696-903d32c2a678 -->","subChapters":[]}]},{"id":"9f8089b4-aaa0-5590-8f74-080099843594","slug":"how-to-treat","fullItemName":"How to treat","depth":3,"htmlHeader":"<!-- begin field ade761b0-ecdc-40d9-ab77-2f0020666bac --><h3>How should I treat an adult with vitamin D deficiency?</h3><!-- end field ade761b0-ecdc-40d9-ab77-2f0020666bac -->","summary":null,"htmlStringContent":"<!-- begin item 881c6283-4990-49bd-855e-1bc8efa436a2 --><!-- begin field 210ad11d-32ee-4b6a-92ec-08693ec6eec8 --><ul><li><strong>Consider the need for referral or seeking specialist advice.</strong><ul><li><strong>Refer to an appropriate specialist (using clinical judgement to decide on the urgency) if</strong> a serious underlying condition, such as cancer or a malabsorption disorder (for example Crohn's disease), is suspected. See the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/background-information/causes/\">Causes</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/diagnosis/differential-diagnosis/\">Differential diagnosis</a>.</li><li><strong>Refer or seek specialist advice (depending on clinical judgement) if the person:</strong><ul><li>Has a fragility fracture, documented osteoporosis, or high fracture risk, or is being treated with an antiresorptive drug for bone disease.</li><li>Has raised parathyroid hormone levels.</li><li>Is taking an antiepileptic drug or an oral corticosteroid, or is on long-term treatment with other <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/background-information/causes/\">drugs</a> known to cause vitamin D deficiency, such as colestyramine.</li><li>Has a malabsorption disorder (for example Crohn's disease) or other <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/background-information/causes/\">condition</a> known to cause vitamin D deficiency, such as chronic kidney disease.</li><li>Has a co-existing condition associated with increased sensitivity to vitamin D (such as sarcoidosis, tuberculosis, lymphoma, or primary hyperparathyroidism).</li><li>Is a pregnant woman.</li><li>Has an unexplained deficiency.<strong> </strong></li></ul></li></ul></li><li><strong>Choose the most appropriate vitamin D preparation for the person.</strong><ul><li>Vitamin D<sub>2</sub> is recommended for strict vegans as it is derived from plant sources. There are also vitamin D preparations for people with peanut or soya allergy and people with halal or kosher requirements.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/prescribing-information/high-dose-vitamin-d/#contraindications-cautions\">Available preparations</a> for more information.</li></ul></li><li><strong>Choose the most appropriate treatment regimen.</strong><ul><li><strong>For the treatment of vitamin D deficiency,</strong> the recommended treatment is based on fixed loading doses of vitamin D (up to a total of about 300,000 international units [IU]) given either as weekly or daily split doses, followed by lifelong maintenance treatment of about 800 IU a day. Higher doses of up to 2000 IU a day, occasionally up to 4000 IU a day, may be used for certain groups of people, for example those with malabsorption disorders.<ul><li>Several treatment regimens are available, including 50,000 IU once a week for 6 weeks (300,000 IU in total), 20,000 IU twice a week for 7 weeks (280,000 IU in total), or 4000 IU daily for 10 weeks (280,000 IU in total).</li></ul></li><li><strong>For the treatment of vitamin D insufficiency, </strong>maintenance doses should be started without the use of loading doses.</li></ul></li><li><strong>Calculate dietary calcium intake.</strong><ul><li>Several online calcium calculators are available, such as the <a href=\"http://www.cgem.ed.ac.uk/research/rheumatological/calcium-calculator\" data-hyperlink-id=\"13ee918f-760b-4f7f-92b9-a98c00e386be\">Institute of Genetics and Molecular Medicine calcium calculator</a>.</li><li>For people with inadequate calcium intake (less than 700 mg a day for most people or less than 1000 mg a day for people with osteoporosis) or people with confirmed hypocalcaemia, advise on dietary measures to correct this.<ul><li>See the British Dietetic Association (BDA) factsheet on <a href=\"https://www.bda.uk.com/foodfacts/Calcium.pdf\" data-hyperlink-id=\"929629eb-6c6d-4341-9197-a98c00e386d5\">calcium</a> (available at <a href=\"https://www.bda.uk.com/\" data-hyperlink-id=\"eed7c0ae-8e43-4b18-8c9a-a98c00e3872c\">www.bda.uk.com</a>) for information on how the daily calcium intake can be achieved.</li><li>Dietary calcium deficiency is common in people with a low meat and milk product intake and may be significantly exacerbated where there is a high dietary intake of phytate (contained in chapatti flour, wholegrain, and wholemeal flour), which binds calcium in the intestine. </li></ul></li><li><strong>For people who are unable or unwilling to increase their dietary calcium, </strong>consider the need for <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/prescribing-information/calcium-supplements/#available-preparations\">supplemental calcium</a> (in addition to high-dose vitamin D) — consider seeking specialist advice.</li><li>Combined calcium and vitamin D preparations (such as Calcichew D3®) are available; however, they are not recommended for people on high-dose vitamin D treatment because they contain very low levels of vitamin D (200–400 IU per tablet) and may result in high dosing of calcium, thereby increasing the risk of hypercalcaemia.</li></ul></li><li><strong>Advise the person:</strong><ul><li>To seek medical advice if they develop any <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/prescribing-information/high-dose-vitamin-d/#adverse-effects\">adverse effects</a> during treatment with high-dose vitamin D, such as nausea and vomiting.</li><li>On <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/management/management/#lifestyle-advice\">lifestyle measures</a> to reduce the risk of recurrence.</li></ul></li><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/management/management/#follow-up\">Follow up</a><em> </em></strong><strong>the person </strong>to ensure that vitamin D deficiency/insufficiency has been treated and to assess for <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/prescribing-information/high-dose-vitamin-d/#adverse-effects\">vitamin D toxicity</a><em> </em>(although this is unlikely at the recommended doses).<ul><li>Be aware that vitamin D treatment can unmask previously undiagnosed primary hyperparathyroidism.</li></ul></li></ul><!-- end field 210ad11d-32ee-4b6a-92ec-08693ec6eec8 --><!-- end item 881c6283-4990-49bd-855e-1bc8efa436a2 -->","subChapters":[{"id":"908531e6-dc66-595d-bc68-2a57ef76f5a3","slug":"basis-for-recommendation-583","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c4165248-241f-40ee-90c3-c7ae07e1f3b7 --><h4>Basis for recommendation</h4><!-- end field c4165248-241f-40ee-90c3-c7ae07e1f3b7 -->","summary":null,"htmlStringContent":"<!-- begin item 583084a9-1123-4fac-82f4-16cbf4601f09 --><!-- begin field 53816fa2-e7d9-45c5-916f-ee3b38398684 --><p>These recommendations are largely based on the National Osteoporosis Society (NOS) guideline <em>Vitamin D and bone health: a practical clinical guideline for patient management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">National Osteoporosis Society, 2013</a>], local vitamin D guidelines issued by the North of Tyne [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">Pearce et al, 2011</a>], Barts and The London School of Medicine and Dentistry [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">Hull and Anastasiadis, 2011</a>], and NHS Wales [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">NHS Wales, 2014</a>], and expert opinion in review articles on vitamin D deficiency [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">Pearce and Cheetham, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">BMJ, 2016</a>].</p><h5>Arranging referral if a serious underlying cause is suspected</h5><ul><li>This recommendation is based on what CKS considers to be good clinical practice.</li></ul><h5>Arranging referral or seeking specialist advice in certain groups</h5><ul><li>This recommendation aims to ensure that the appropriate dose, duration, and treatment regimen of vitamin D is given. For example:<ul><li>People with malabsorption disorders or chronic liver disease would need higher doses of vitamin D (for example ergocalciferol tablets up to 40,000 international units [IU] a day) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">BNF 72, 2016</a>], preferably given parenterally to improve absorption [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">Pearce and Cheetham, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">NHS Wales, 2014</a>].</li><li>People with kidney disease that is severe enough to impair the hydroxylation of vitamin D may require treatment with a short-acting, potent vitamin D analogue, such as alphacalcidol or calcitriol (specialist initiation only) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">BNF 72, 2016</a>].</li><li>People with co-existing conditions associated with increased sensitivity to vitamin D are at increased risk of vitamin D toxicity and therefore need lower doses of vitamin D and more frequent monitoring [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">Hull and Anastasiadis, 2011</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">National Osteoporosis Society, 2013</a>].</li><li>The effect of high-dose vitamin D on pregnancy is unclear:<ul><li>The UK teratology information services (UKTIS) states that there are insufficient data available in the literature to provide a detailed risk assessment of high-dose vitamin D treatment during pregnancy, but it should not be withheld if needed, considering the possible risks associated with poor maternal vitamin D status during pregnancy. However, other risk factors may be present in individual cases which may independently increase the risk of adverse pregnancy outcome. UKTIS states reminds clinicians of the importance of considering such factors when performing case-specific risk assessments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">UKTIS, 2013</a>]. Expert opinion of a reviewer of this CKS topic is that treating a 'possible risk' by giving high-dose vitamin D to pregnant women seems to be questionable.</li><li>The <em>Institute of Medicine (IOM): Dietary reference intakes for calcium and vitamin D</em> recommends a daily dose of 600 IU of vitamin D for pregnant and breastfeeding women, and states that a maximum daily dose of 4000 IU of vitamin D is safe during pregnancy and breastfeeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">IOM, 2010</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">Ross and Grahame, 2011</a>].</li><li>Expert opinion in the American Congress of Obstetricians and Gynecologists (ACOG) committee publication <em>Vitamin D: screening and supplementation during pregnanc</em>y is that most experts agree that 1000–2000 IU of vitamin D a day is safe during pregnancy and breastfeeding. However, it was highlighted that the use of higher dose regimens for the treatment of vitamin D deficiency during pregnancy has not been studied [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">ACOG, 2011</a>].</li></ul></li></ul></li></ul><h5>Choosing the most appropriate vitamin D preparation</h5><ul><li>NOS recommends vitamin D<sub>3 </sub>as the preparation of choice for the treatment of vitamin D deficiency [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">National Osteoporosis Society, 2013</a>].</li><li>The current consensus is that it raises serum vitamin D concentrations more effectively than vitamin D<sub>2</sub> (due to higher affinities for liver enzymes, plasma vitamin D binding protein, and vitamin D receptors) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">UKMi, 2016</a>].<ul><li>Results from studies (identified by SACN) that compared the effectiveness of vitamin D<sub>2</sub> and vitamin D<sub>3</sub> in raising serum 25-hydroxyvitamin D (25[OH]D) concentrations have been inconsistent, but most of the evidence supports the suggestion that vitamin D<sub>3</sub> is more effective than vitamin D<sub>2</sub> in raising serum 25(OH)D concentrations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">SACN, 2016</a>].</li></ul></li><li>Vitamin D<sub>2</sub> is recommended for strict vegans because it is derived from plant sources, unlike vitamin D<sub>3</sub> which is derived from animal sources [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">UKMi, 2016</a>].</li></ul><h5>Choosing the most appropriate treatment regimen</h5><ul><li>The recommendation on treating vitamin D deficiency is based on expert opinion in the NOS guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">National Osteoporosis Society, 2013</a>].<ul><li>NOS acknowledges that in theory, a titrated treatment approach is likely to be more effective than a fixed loading dose regime at restoring vitamin D levels and reducing the risk of vitamin D toxicity. However, these advantages do not outweigh the disadvantages of the increased costs of titration testing and the effect of increasing complexity on the prescriber and the person. <ul><li>Loading with oral vitamin D is preferred to parenteral vitamin D for most people because there is evidence that vitamin D stores are replenished more rapidly with oral preparations, and bioavailability is more predictable.</li></ul></li><li>The recommendation on treating vitamin D insufficiency is extrapolated from the NOS guideline, which states that where correction of vitamin D deficiency is less urgent, maintenance treatment may be started without the use of loading doses. </li></ul></li></ul><h5>Vitamin D treatments not routinely recommended</h5><ul><li>Short-acting, potent vitamin D analogues (such as alfacalcidol and calcitriol) and annual depot vitamin D treatments (oral or parenteral) are not routinely recommended because they have been shown to cause toxicity or not to work [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">National Osteoporosis Society, 2013</a>].</li><li>Short-acting, potent vitamin D analogues should only be prescribed in people with renal impairment that is severe enough to impair the hydroxylation of vitamin D to its active metabolite (specialist initiation only) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">BNF 72, 2016</a>].</li><li>Liquid 'special preparations' of vitamin D (unlicensed) are not routinely recommended for use in adults because more cost-effective alternatives are available [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">Hull and Anastasiadis, 2011</a>].</li></ul><h5>Ensuring adequate calcium intake </h5><ul><li>Adequate levels of both vitamin D and calcium are needed to ensure optimum serum calcium levels, and it is important to ensure that both are maintained to prevent long-term adverse effects on the bones [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">BMJ, 2016</a>].</li><li>The recommendation to consider the need for supplemental calcium only when an adequate dietary intake of calcium cannot be achieved is extrapolated from expert opinion in the National Osteoporosis Guideline Group (NOGG) guideline <em>Osteoporosis: clinical guideline for prevention and treatment</em>, which states that it may be prudent to increase dietary calcium intake and use vitamin D alone where the use of calcium and vitamin D supplementation might otherwise be considered. In their expert opinion [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">NOGG, 2016</a>]:<ul><li>Compliance and persistence with calcium-containing supplements is poor (possibly due to the unpalatability of the calcium component).</li><li>High dietary calcium does not seem to carry the same increased risk of cardiovascular events as has been suggested for calcium supplements in several studies (although these studies have been widely criticised and the putative association requires further clarification).</li></ul></li><li> There are no preparations containing high-dose vitamin D in combination with calcium. NOS advises that the available calcium and vitamin D combination products (such as Calcichew-D<sub>3</sub>®) should not be used as sources of vitamin D for treating vitamin D deficiency because of the resulting high doses of calcium [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">National Osteoporosis Society, 2013</a>].</li><li>The recommended dose of calcium (1–2 g) is in line with the Institute of Medicine (IOM)'s recommended dietary calcium allowance for adults aged 18 years and older [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">IOM, 2010</a>].</li></ul><h5>Giving lifestyle advice</h5><ul><li>This recommendation is based on expert opinion in the NOS guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">National Osteoporosis Society, 2013</a>] and a review article on vitamin D deficiency [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">BMJ, 2016</a>].</li></ul><h5>Following up to ensure vitamin D repletion and to assess for vitamin D toxicity</h5><ul><li>This recommendation is based on expert opinion in the NOS guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">National Osteoporosis Society, 2013</a>], a vitamin D guideline issued by Barts and The London School of Medicine and Dentistry [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">Hull and Anastasiadis, 2011</a>], and review articles on vitamin D deficiency [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">Pearce and Cheetham, 2010</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">BMJ, 2016</a>].</li><li>The NOS guideline states that the aims of monitoring people on high-dose vitamin D treatment are to detect people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">National Osteoporosis Society, 2013</a>]:<ul><li>Who remain deficient after loading.</li><li>Who become deficient during maintenance.</li><li>In whom vitamin D treatment uncovers sub-clinical primary hyperparathyroidism.</li></ul></li><li>Expert opinion in the Scientific Advisory Committee on Nutrition (SACN) report on<em> Vitamin D and health</em> is that vitamin D doses of 300,000 IU at intervals of 3 months or longer would not be expected to cause adverse effects in adults; however, there is greater uncertainty about the effects of larger doses, which may cause hypercalcaemia in some people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">SACN, 2016</a>].<ul><li>However, the SACN report identified three studies that reported adverse effects with lower doses of vitamin D:<ul><li>One randomized controlled trial (RCT) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">Sanders et al, 2010</a>] of women in Australia (n = 2256 women aged 70 years and older) reported an increased risk of fracture in the vitamin D<sub>3</sub> supplemented group (single annual dose of 12,500 micrograms/500,000 IU for 3–5 years) compared with the placebo group (incident ratio rate [IRR] =1.15; 95% CI, 1.02–1.30 for fractures; IRR, 1.26; 95% CI, 1.00–1.59 for falls). </li><li>A second RCT [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">Bischoff-Ferrari et al, 2016</a>] of community-dwelling adults (n = 200 adults aged 70 years and older with a prior fall) randomized to receive a monthly dose of either 600 micrograms (24,000 IU) vitamin D<sub>3</sub>, 1500 micrograms (60,000 IU) vitamin D<sub>3</sub>, or 600 micrograms (24,000 IU) vitamin D<sub>3</sub> plus 300 micrograms of 25(OH)D<sub>3</sub> for 12 months reported that the incidence of falls was significantly higher in the 1500 micrograms (60,000 IU) vitamin D<sub>3</sub> group (66.9%; 95% CI, 54.4–77.5%) and the 600 micrograms (24,000 IU) vitamin D<sub>3</sub> plus 300 microgram 25(OH)D<sub>3</sub> group (66.1%; 95% CI, 53.5–76.8%) compared with the 600 microgram (24,000 IU) vitamin D<sub>3</sub> group (47.9%; 95% CI, 35.8–60.3%) (p = 0.048).</li><li>Another study [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">Smith et al, 2007</a>] reported a significant increase in non-vertebral fracture in women (but not men) given an annual intra-muscular injection of vitamin D<sub>2</sub> (7500 micrograms/300,000 IU). No effect was observed on the frequency of falls.</li></ul></li></ul></li></ul><!-- end field 53816fa2-e7d9-45c5-916f-ee3b38398684 --><!-- end item 583084a9-1123-4fac-82f4-16cbf4601f09 -->","subChapters":[]}]},{"id":"99a4c4fc-e473-5a2f-9e58-abc7d8d0f5de","slug":"lifestyle-advice","fullItemName":"Lifestyle advice","depth":3,"htmlHeader":"<!-- begin field 8cd5fed5-47a6-4acd-8811-8399d63cc728 --><h3>What lifestyle advice should I give a person with vitamin D deficiency?</h3><!-- end field 8cd5fed5-47a6-4acd-8811-8399d63cc728 -->","summary":null,"htmlStringContent":"<!-- begin item 76a0ea7c-a567-440d-b409-e473e062e0a7 --><!-- begin field 26387562-d71b-4902-b452-8a24a548adaa --><p><strong>Give information and advice on:</strong></p><ul><li><strong>Safe sun exposure.</strong> Advise that:<ul><li>Exposing commonly uncovered areas of the skin (such as the forearms and hands) for short periods when in strong sunlight provides vitamin D. Longer periods of exposure may be needed for those with darker skin.  <ul><li>Many people will have experienced sunburn. They can use this experience to know what their skin looks like normally, how it reacts to sunlight, how long they can be exposed without risking sunburn, and how to protect their skin accordingly.</li><li>Advise that skin that is not usually exposed to sunlight (for example the back, abdomen and shoulders) is particularly likely to burn, so extra care is needed.</li></ul></li><li>Prolonged exposure to strong sunlight (for example leading to burning or tanning) does not lead to excess production of vitamin D, as a regulation mechanism exists to destroy excess vitamin D, but increases the risk of skin cancer.</li><li>Between March and October in the UK, people should protect their skin from burning by covering up with suitable clothing (such as long-sleeved tops, a broad-brimmed hat, or long skirts and trousers); seeking shade (especially between 11am and 3pm); and applying sunscreen, which should:<ul><li>Meet minimum standards for ultraviolet A (UVA) protection — the label should have the letters 'UVA' in a circle logo and should preferably state that it provides good UVA protection (for example at least '4-star UVA protection').</li><li>Provide at least sun protection factor (SPF) 15 to protect against UVB.</li><li>Be applied liberally and frequently, according to the manufacturer's instructions. If the sunscreen is applied too thinly, the amount of protection it gives is reduced.</li></ul></li><li>Sunbeds are not an effective method of protecting against vitamin D deficiency because they emit high levels of UVA, which do not contribute to vitamin D synthesis but increase the risk of skin cancer.</li></ul></li><li><strong>Dietary intake of vitamin D. </strong>Advise that:<ul><li>It is important to maintain dietary intake of vitamin D by taking vitamin D supplements, especially during the winter months, as it is difficult to obtain sufficient vitamin D from food sources alone because they are limited.</li><li>Rich sources include cod liver oil (this also contains vitamin A which can be harmful in high doses and should be avoided in pregnancy), oily fish (such as salmon, mackerel, and sardines). Egg yolk, meat, offal, milk, mushrooms, and fortified foods (such as fat spreads and some breakfast cereals and yoghurts) contain small amounts.</li></ul></li><li><strong>Dietary intake of calcium. </strong>Advise that:<ul><li>It is also important to maintain dietary intake of calcium, as both calcium and vitamin D are needed to prevent long-term adverse effects on the bones.</li><li>Rich sources of calcium include dairy foods (milk, cheese, and yoghurts) and tinned sardines with bones. </li></ul></li><li><strong>Adherence to long-term supplementation.</strong><ul><li>Explain that long-term supplementation with vitamin D and, where necessary, calcium should be adhered to in order to prevent recurrence of deficiency and to maintain bone health.</li></ul></li><li><strong>Sources of additional information.</strong><ul><li>The British Dietetic Association has useful factsheets on <a data-hyperlink-id=\"6861d93d-446b-4fe5-9964-a98e014bd1b6\" href=\"https://www.bda.uk.com/foodfacts/VitaminD.pdf\">Vitamin D</a> and <a data-hyperlink-id=\"37b7aac5-d0b2-4a58-bfb0-a98e014bd267\" href=\"https://www.bda.uk.com/foodfacts/Calcium.pdf\">Calcium</a> (available at <a data-hyperlink-id=\"f6dfc51e-b790-4c74-bfd8-a98e014bd2f7\" href=\"https://www.bda.uk.com/\">www.bda.uk.com</a>).</li><li>The NHS website has a useful publication on <a data-hyperlink-id=\"58125792-5bfa-4c9e-b047-a98e014bd544\" href=\"https://www.nhs.uk/conditions/vitamins-and-minerals/vitamin-d/\">Vitamins and minerals - Vitamin D</a> (available at <a data-hyperlink-id=\"59e61dbe-a80d-4d58-ba75-a98e014bd590\" href=\"https://www.nhs.uk/conditions/\">www.nhs.uk</a>).</li><li>The Met Office (<a data-hyperlink-id=\"986c9453-2147-4ace-b604-a98e014bd5b8\" href=\"http://www.metoffice.gov.uk/\" target=\"_top\">www.metoffice.gov.uk</a>) provides information on the UV index, which is an indicator of the sun's strength for a given location, date and time. This information, combined with skin type and behaviour, can be used to assess someone's risk of sunburn.</li></ul></li></ul><!-- end field 26387562-d71b-4902-b452-8a24a548adaa --><!-- end item 76a0ea7c-a567-440d-b409-e473e062e0a7 -->","subChapters":[{"id":"9f1e430d-f5bc-5a1a-9f96-ce3b4d646d07","slug":"basis-for-recommendation-6ac","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 5c470959-3c8f-49d0-af40-0002c09c66db --><h4>Basis for recommendation</h4><!-- end field 5c470959-3c8f-49d0-af40-0002c09c66db -->","summary":null,"htmlStringContent":"<!-- begin item 6acbdf98-8c1e-43d6-a511-ee3e06b4fe0a --><!-- begin field 19b5b307-fcb7-4397-904c-7ae611259092 --><p>These recommendations are largely based on expert opinion in the National Institute for Health and Care Excellence (NICE) guidelines <em>Sunlight exposure: risks and benefits </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">NICE, 2016</a>]<em> </em>and<em> Vitamin D: increasing supplement use in at-risk groups </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">NICE, 2014</a>]<strong>, </strong>the Scientific Advisory Committee on Nutrition (SACN) guideline <em>Vitamin D and heal</em><em>th</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">SACN, 2016</a>], and the Consensus Vitamin D position statement (which represents the unified views of the British Association of Dermatologists, Cancer Research UK, Diabetes UK, the Multiple Sclerosis Society, the National Heart Forum, the National Osteoporosis Society and the Primary Care Dermatology Society) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">BAD et al, 2010</a>].</p><ul><li>NICE does not describe the exact amount of sunlight exposure sufficient to stimulate cutaneous vitamin D production, but states that 'exposing commonly uncovered areas of skin, such as forearms and hands, for short periods when in strong sunlight provides vitamin D. (Longer periods of exposure may be needed for those with darker skin.)' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">NICE, 2016</a>]. This is in line with recommendation in the SACN report and the Consensus Vitamin D position statement.<ul><li>SACN were unable to make any recommendations regarding the amount of sunlight exposure that would be needed during the summer months to maintain serum 25-hydroxyvitamin D (25[OH]D) levels of 25 nmol/L or greater during the winter months, as environmental and personal factors greatly affect cutaneous vitamin D production [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">SACN, 2016</a>].</li><li>Expert opinion in the consensus position statement is that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">BAD et al, 2010</a>]:<ul><li>It is impractical to offer a one-size-fits-all recommendation for the amount of sun exposure that people need to make sufficient vitamin D, as this varies according to a number of factors (environmental, physical, and personal).</li><li>The time needed to make sufficient vitamin D is typically short and less than the amount of time needed for skin to redden and burn. Regularly going outside for a matter of minutes around midday without sunscreen should be enough.</li><li>When it comes to sun exposure, little and often is best, and the more skin that is exposed, the greater the chance of making enough vitamin D before burning.</li><li>People should get to know their own skin to understand how long they can spend outside before risking sunburn.</li></ul></li></ul></li><li>Expert opinion in the British Medical Journal (BMJ) Best Practice review article <em>Vitamin D deficiency</em> is that usually, exposure of the arms and legs (with sun protection on the face) for about 5 to 30 minutes (depending on degree of skin pigmentation, time of day, season, latitude, and age of the person) between 10 am and 3 pm twice a week is sufficient for vitamin D synthesis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">BMJ, 2016</a>].</li></ul><!-- end field 19b5b307-fcb7-4397-904c-7ae611259092 --><!-- end item 6acbdf98-8c1e-43d6-a511-ee3e06b4fe0a -->","subChapters":[]}]},{"id":"33a2a1c4-7243-5374-a1c9-262cfd0a3e68","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field dca08d70-c6cd-40a0-99b9-f700d8d0f99e --><h3>How should I follow up a person on high-dose vitamin D treatment?</h3><!-- end field dca08d70-c6cd-40a0-99b9-f700d8d0f99e -->","summary":null,"htmlStringContent":"<!-- begin item 0512e29d-16d6-4025-af16-14580d7c7cff --><!-- begin field ed92e752-6087-458c-83f0-8d57f4cd2a00 --><ul><li><strong>Within one month of completing high-dose vitamin D treatment, </strong>check adjusted serum calcium levels. Consider checking serum calcium levels more regularly (for example every 1–2 weeks in the first months of treatment) in people receiving calcium supplements in addition to high-dose vitamin D treatment.<ul><li><strong>If hypercalcaemia is identified:</strong><ul><li>Assess the person's state of hydration, and consider admission if the person is dehydrated.</li><li>If the person is taking calcium supplements, advise them to stop taking them.</li></ul></li><li><strong>If calcium levels are normal:</strong><ul><li>Do not recommend long-term calcium supplements. </li><li>If the person is taking calcium supplements, advise them to stop taking them.</li></ul></li><li><strong>If hypocalcaemia is identified:</strong><ul><li>Advise the use of an over-the-counter calcium supplement containing 1–2 g of calcium. This may be needed long term (in addition to vitamin D maintenance treatment) for people with <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/management/management/#how-to-treat\">inadequate dietary calcium intake</a>. </li><li>If the person is already taking a calcium supplement, refer to secondary care.</li></ul></li></ul></li><li><strong>After 3–6 months of treatment with high-dose vitamin D, </strong>check serum 25-hydroxyvitamin D (25[OH]D) levels. <ul><li><strong>If serum 25(OH)D levels are below 50 nmol/L, </strong>refer to secondary care for consideration of possible causes, including poor compliance with treatment, <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/prescribing-information/high-dose-vitamin-d/#drug-interactions\">drug interactions</a>, or an <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/background-information/causes/\">underlying disease</a>, such as renal disease, liver disease, or malabsorption.</li><li><strong>If serum 25(OH)D levels are greater than 50 nmol/L and there are no <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/prescribing-information/high-dose-vitamin-d/#adverse-effects\">signs</a> of hypercalcaemia:</strong><ul><li>Prescribe a daily maintenance dose of 800 international units (IU). (Higher doses of up to 2000 IU a day, occasionally up to 4000 IU a day, may be used for certain groups of people, for example those with malabsorption disorders.) </li><li>Reinforce <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/management/management/#lifestyle-advice\">lifestyle advice</a><em> </em>to prevent recurrence.</li></ul></li><li><strong>If symptoms and signs have not improved despite satisfactory 25(OH)D levels, </strong>consider an <a class=\"topic-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/diagnosis/differential-diagnosis/\">alternative diagnosis</a>.</li></ul></li></ul><!-- end field ed92e752-6087-458c-83f0-8d57f4cd2a00 --><!-- end item 0512e29d-16d6-4025-af16-14580d7c7cff -->","subChapters":[{"id":"f846324b-36c4-5de0-a875-e0dc417b1842","slug":"basis-for-recommendation-d16","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1e3afc6b-c82c-458d-bee3-a04b29331139 --><h4>Basis for recommendation</h4><!-- end field 1e3afc6b-c82c-458d-bee3-a04b29331139 -->","summary":null,"htmlStringContent":"<!-- begin item d165befb-435a-452e-bc45-4a040aff1429 --><!-- begin field 4bba277b-e8bb-4bad-b8ea-5ae5cc42e6c1 --><h5>Checking adjusted serum calcium levels</h5><ul><li>The National Osteoporosis Society (NOS) guideline <em>Vitamin D and bone health: a practical clinical guideline for patient management</em> recommends checking adjusted serum calcium levels within 1 month of completing the loading regimen, in case primary hyperparathyroidism has been unmasked [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">National Osteoporosis Society, 2013</a>].</li><li>Expert opinion in the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">BNF 72, 2016</a>] and in local vitamin D guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">Hull and Anastasiadis, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">Camden Clinical Commissioning Group NHS, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">NHS Wales, 2014</a>] is that serum calcium levels should be checked more regularly in people who are also receiving calcium supplements, to determine how long calcium supplementation is needed and to reduce the risk of hypercalcaemia.<ul><li>One expert reviewer of this CKS topic suggests that there is good evidence to support this recommendation but recognised that this more regular blood testing does not happen in clinical practice. CKS therefore recommends considering the need for more regular checks in this group of people.</li></ul></li></ul><h5>Checking serum hydroxyvitamin D (25[OH]D) levels</h5><ul><li>Based on evidence suggesting that a new steady state 25(OH)D level is reached after about 3 months of vitamin D treatment (6 months in another study), NOS recommends that a minimum of 3 months treatment must be given before checking 25(OH)D levels and that it may be more prudent to wait until after 6 months have passed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">National Osteoporosis Society, 2013</a>].</li><li>The recommendation to refer people who have not responded to vitamin D treatment is based on expert opinion in the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">BNF 72, 2016</a>]and is in line with recommendations in the NOS guideline <em>Vitamin D and bone health: a practical clinical guideline for management in children and young people</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">National Osteoporosis Society, 2015</a>].</li></ul><h5>Daily maintenance dose</h5><ul><li>Following treatment for vitamin D deficiency, people will generally need lifelong preventative vitamin D treatment, as lifestyle changes may not be effective enough to maintain optimum vitamin D levels [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">Pearce et al, 2011</a>]. In addition, people who are unable to take sufficient dietary calcium will require long-term calcium supplements [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">NHS Wales, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">NHS Wales, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">BNF 72, 2016</a>].</li><li>The NOS guideline <em>Vitamin D and bone health: a practical clinical guideline for patient management </em>states that maintenence doses may be considered after high-dose vitamin D treatment, with doses equivalent to 800–2000 international units (IU) daily (occasionally up to 4000 IU daily) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">National Osteoporosis Society, 2013</a>]. An expert opinion of a reviewer of this CKS topic is that 800 IU a day is sufficient for most people, except people with malabsorption syndromes.</li><li>The recommendation on when to consider an alternative diagnosis is extrapolated from the NOS vitamin D guideline for children and young people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/references/\">National Osteoporosis Society, 2015</a>].</li></ul><!-- end field 4bba277b-e8bb-4bad-b8ea-5ae5cc42e6c1 --><!-- end item d165befb-435a-452e-bc45-4a040aff1429 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}